Insights
Search Results
Client Highlights
6.03.26
Wilson Sonsini Advises Luminopia on Licensing Agreement with ROHTO
On June 2, 2026, Luminopia, Inc., a digital health company pioneering a new class of treatments for neuro-visual disorders, announced its first international licensing agreement with ROHTO Pharmaceutical Co., LTD, a Japanese multinational corporation specializing in consumer products and pharmaceuticals. Wilson Sonsini Goodrich & Rosati advised Luminopia on the transaction.
Client Highlights
4.06.26
Wilson Sonsini Advises Soleno Therapeutics on $2.9 Billion Acquisition by Neurocrine
On April 6, 2026, Neurocrine Biosciences and Soleno Therapeutics announced that Neurocrine has entered into a definitive agreement to acquire Soleno for $53.00 per share in cash, representing a total transaction equity value of $2.9 billion. Wilson Sonsini Goodrich & Rosati is advising Soleno on the transaction.
Client Highlights
3.24.26
Firm Advises Dimer Health on $13.5 Million Series A Financing
On March 23, 2026, Dimer Health, a clinician-led, AI-native transitional care medicine company, announced $13.5 million in Series A financing led by Team8 and Bill Ackman's Table Management, with participation from existing investors Silver Circle and TechAviv. The round brings the company's total funding to $20 million and will support national expansion of Dimer's dedicated post-discharge clinical service line, now operating across eight states. Wilson Sonsini Goodrich & Rosati advised Dimer on the transaction.
Client Highlights
3.13.26
Wilson Sonsini Advises Enodia Therapeutics on Purchase Agreement with Kezar Life Sciences
On March 12, 2026, Enodia Therapeutics (Enodia), a biotechnology company developing novel small-molecule therapies for targeted protein degradation at the point of synthesis, and Kezar Life Sciences, a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, announced that Enodia has acquired Kezar’s assets from its Sec61-based discovery and development program. Under the terms of the purchase agreement between Enodia and Kezar, Kezar will receive an initial upfront payment totaling $1 million, and will receive future payments upon achievement of certain development, regulatory and commercialization milestones, for a potential total of up to $127 million. Enodia has also agreed to pay tiered royalties on net sales. Wilson Sonsini Goodrich & Rosati advised Enodia on the transaction.
Client Highlights
3.09.26
Wilson Sonsini Advises Lead Investor on SHINE’s $240 Million Equity Funding
On February 27, 2026, SHINE Technologies, a nuclear fusion company, announced it has raised $240 million in equity funding led by NantWorks founder Dr. Patrick Soon-Shiong, with additional participation from Fidelity Management & Research Company, Sumitomo Corporation of Americas, Pelican Energy Partners, Deerfield Management, Oaktree Capital Management, and other existing investors. Wilson Sonsini Goodrich & Rosati advised lead investor OZ Shine LLC—a new investment company led by Dr. Soon-Shiong—on the transaction.
Client Highlights
3.04.26
Wilson Sonsini Advises Sinopia Biosciences on Target Discovery Collaboration with Ono Pharmaceutical
On March 3, 2026, Sinopia Biosciences, a biotechnology company advancing novel therapeutics discovered using its proprietary LEADS®(LEarn And DiScover) drug discovery platform, announced a target discovery collaboration with Ono Pharmaceutical focused on an undisclosed group of rare metabolic disorders with significant unmet medical need. Under the agreement, Sinopia will apply its proprietary metabolomics-driven discovery platform to identify and validate novel therapeutic targets aimed at addressing the underlying biochemical dysfunction that drives disease progression. Ono Pharmaceutical may advance targets, identified through the collaboration, toward the development of new medicines for affected patients. Wilson Sonsini Goodrich & Rosati advised Sinopia Biosciences on the transaction.
Client Highlights
1.21.26
Wilson Sonsini Advises Pacira BioSciences on Agreement with LG Chem
On January 13, 2026, Pacira BioSciences, the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, announced it has entered into an agreement with LG Chem designed to expand access to opioid-sparing postsurgical pain control for patients in select Asian-Pacific markets. Through this partnership, LG Chem has the exclusive rights to commercialize EXPAREL® (bupivacaine liposome injectable suspension), Pacira’s long-acting, local analgesic for postsurgical pain management in the region. Wilson Sonsini Goodrich & Rosati advised Pacira on the transaction.
Client Highlights
11.06.25
Wilson Sonsini Advises Pacira BioSciences on License Agreement with AmacaThera
On November 4, 2025, Pacira BioSciences, a leader in non-opioid pain management, announced an exclusive worldwide license and collaboration agreement with AmacaThera to develop and commercialize AMT-143, an investigational long‑acting formulation of the non‑opioid analgesic ropivacaine for postsurgical pain control. Wilson Sonsini Goodrich & Rosati advised Pacira BioSciences on the transaction.
Client Highlights
7.25.25
Wilson Sonsini Advises Revival on Strategic Partnership with Olympus
On July 25, 2025, Revival Healthcare Capital (Revival), an investment firm focused on transformative external innovation partnerships in MedTech, announced a strategic partnership with Olympus Corporation (Olympus), a global healthcare leader committed to making people’s lives healthier, safer, and more fulfilling through advanced medical technologies and solutions. The partnership is aimed at harnessing external innovation to accelerate development and market entry for an endoluminal robotics platform initially targeting gastrointestinal (GI) treatments. Wilson Sonsini Goodrich & Rosati advised Revival on the transaction and on fund matters related to the transaction.
Client Highlights
2.27.25
Wilson Sonsini Advises Cyrano Therapeutics on Option Agreement with KYORIN
On February 18, 2025, Cyrano Therapeutics, a clinical-stage regenerative medicine company pioneering the development of treatments for smell loss, announced that it entered into an option agreement with KYORIN Pharmaceutical. Under the agreement, KYORIN has an option to license CYR-064 for development and commercialization in Japan and will pay an option fee. Upon exercising the option and entering into a licensing agreement, KYORIN will provide Cyrano with an upfront payment, milestone payments tied to the progress of developing and commercializing CYR-064, and royalties based on a specified percentage of net sales following its launch. Wilson Sonsini Goodrich & Rosati advised Cyrano on the transaction.
Client Highlights
12.11.24
Wilson Sonsini Advises Cimeio Therapeutics on Partnership with Kyowa Kirin
On December 9, 2024, Cimeio Therapeutics, an immunotherapy company, announced that it has entered a research collaboration with Kyowa Kirin to develop novel cell therapies. Wilson Sonsini Goodrich & Rosati advised Cimeio on the transaction.
Client Highlights
10.03.24
Wilson Sonsini Advises Aytu BioPharma in Exclusive Agreement with Lupin Pharma Canada Ltd
On October 1, 2024 Aytu BioPharma, Inc., a pharmaceutical company focused on commercializing novel therapeutics, and Lupin Pharma Canada Ltd, a subsidiary of global pharma major Lupin Limited, announced the signing of an exclusive collaboration, distribution and supply agreement for Aytu's Adzenys XR-ODT® and Cotempla XR-ODT® product lines in Canada. Wilson Sonsini Goodrich & Rosati advised Aytu BioPharma on the transaction.
Adzenys XR-ODT extended-release orally disintegrating tablets is a prescription medicine used for the treatment of attention deficit hyperactivity disorder (ADHD) in patients 6 years and above and the only brand FDA-approved as bioequivalent to Adderall XR®. Cotempla XR-ODT is the only extended-release orally disintegrating tablet methylphenidate and is FDA-approved as a once-daily ADHD treatment for patients 6 to 17 years of age. Aytu's ADHD portfolio has experienced rapid growth over the past two years, with prescriptions increasing 16.5 percent during that time. This agreement extends Aytu's reach through the expansion into one of the world's largest ADHD markets outside the United States. In 2023, the Canadian ADHD stimulant market recorded 4.5 million units and $1.1 Billion CAD in gross sales. (Source: IQVIA Canada). Lupin will seek local regulatory approvals and marketing authorizations for both Adzenys XR-ODT and Cotempla XR-ODT, which is expected to occur over the next 18 to 24 months.
Adzenys XR-ODT extended-release orally disintegrating tablets is a prescription medicine used for the treatment of attention deficit hyperactivity disorder (ADHD) in patients 6 years and above and the only brand FDA-approved as bioequivalent to Adderall XR®. Cotempla XR-ODT is the only extended-release orally disintegrating tablet methylphenidate and is FDA-approved as a once-daily ADHD treatment for patients 6 to 17 years of age. Aytu's ADHD portfolio has experienced rapid growth over the past two years, with prescriptions increasing 16.5 percent during that time. This agreement extends Aytu's reach through the expansion into one of the world's largest ADHD markets outside the United States. In 2023, the Canadian ADHD stimulant market recorded 4.5 million units and $1.1 Billion CAD in gross sales. (Source: IQVIA Canada). Lupin will seek local regulatory approvals and marketing authorizations for both Adzenys XR-ODT and Cotempla XR-ODT, which is expected to occur over the next 18 to 24 months.